References
- Lubrano E, Spadaro A. Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies. BMC Musculoskelet Disord. 2014;15:25.
- Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, et al. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):851–858.
- Moots RJ, Mays R, Stephens J, et al. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. Clin Exp Rheumatol. 2015;33(5):737–745.
- Tachkov K, Mitkova Z, Boyadzieva V, et al. Did the introduction of biosimilars influence their prices and utilization? The case of biologic disease modifying antirheumatic drugs (bDMARD) in Bulgaria. Pharmaceuticals. 2021;14(1):64. https://doi.org/10.3390/ph14010064.
- Schabert V, Watson C, Joseph G, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19(8):621–630.
- Boyadzieva V, Stoilov N, Stoilov R, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794.
- Joensuu JT, Aaltonen KJ, Aronen P, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology (Oxford). 2016;55(10):1803–1811. https://doi.org/10.1093/rheumatology/kew264.
- Dalal DS, Zhang T, Shireman TI. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020;50(5):822–826.
- Martínez-López-de-Castro N, Álvarez-Payero M, Samartín-Ucha M, et al. Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. Clin Exp Rheumatol. 2021;39(4):736–745.
- Bonafede M, Joseph G, Princic N, et al. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ. 2013;16(9):1120–1128.
- Gu T, Shah N, Deshpande G, et al. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016;3(4):369–381.
- National Statistical Institute. Population database [Internet]. Available from: www.nsi.bg.
- National Health Insurance Fund. Medicines, medical devices, and cost database [Internet]. Available from: www.nhif.bg. Accessed May 2022.
- World Health Organisation. International statistical classification of diseases and related health problems (ICD 10) [Internet]. Available from: https://www.who.int/standards/classifications/classification-of-diseases.
- National Council on Prices and Reimbursement of Medicinal Products. Price registries [Internet]. Available from: www.ncpr.bg.
- World Health Organisation. Introduction to DDD indicators [Internet]. Available from: https://www.who.int/tools/atc-ddd-toolkit/indicators.
- Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070. DOI: 10.3389/fphar.2018.01070.
- Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in Central and Eastern european countries. Front Pharmacol. 2017;8:288. DOI: 10.3389/fphar.2017.00288.
- Tatangelo M, Tomlinson G, Paterson JM, et al. Health care costs of rheumatoid arthritis: a longitudinal population study. PLoS One. 2021;16(5):e0251334. https://doi.org/10.1371/journal.pone.0251334.
- Chen C-I, Wang L, Wei W, et al. Burden of rheumatoid arthritis among US medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Prac. 2018;2:1316–1319.